VANCOUVER, April 13 /PRNewswire-FirstCall/ - Neovasc Inc. (TSXV: NVC), today announced financial results for the year ended December 31, 2009. “In 2009 Neovasc focused its attention on two primary goals; growing its tissue business and furthering the development of the Neovasc Reducer(TM) product for treating refractory angina. With this tight focus, Neovasc was able to substantially reduce its operating costs and almost double its annual revenues to $3 million, while also making important progress in the Reducer program,” said Alexei Marko, chief executive officer of Neovasc.
